Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.00
+0.17 (0.95%)
Nov 24, 2025, 4:00 PM EST - Market closed
Avalo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 0.19 | 0.44 | 1.92 | 18.05 | 5.4 | 6.7 | Upgrade | |
Revenue Growth (YoY) | -76.59% | -77.08% | -89.34% | 234.40% | -19.42% | -0.76% | Upgrade |
Cost of Revenue | 32.1 | 15.28 | 9.95 | 25.99 | 50.12 | 25.24 | Upgrade |
Gross Profit | -31.91 | -14.84 | -8.02 | -7.94 | -44.72 | -18.54 | Upgrade |
Selling, General & Admin | 21.6 | 17.24 | 10.3 | 13.91 | 24.66 | 19.76 | Upgrade |
Research & Development | 12.99 | 8.8 | 5.12 | 8.05 | 11.21 | 7.26 | Upgrade |
Amortization of Goodwill & Intangibles | - | - | - | 0.04 | 1.55 | 1.74 | Upgrade |
Operating Expenses | 34.59 | 26.04 | 15.42 | 22 | 37.41 | 28.76 | Upgrade |
Operating Income | -66.49 | -40.87 | -23.44 | -29.94 | -82.13 | -47.29 | Upgrade |
Interest Expense | - | - | -3.42 | -4.17 | -2.39 | - | Upgrade |
Interest & Investment Income | 4.58 | 3.32 | - | - | - | 0.05 | Upgrade |
Other Non Operating Income (Expenses) | -37.82 | 30.18 | -0.76 | -0.02 | -0.02 | 0.41 | Upgrade |
EBT Excluding Unusual Items | -99.73 | -7.37 | -27.62 | -34.13 | -84.55 | -46.84 | Upgrade |
Merger & Restructuring Charges | - | - | - | -7.5 | - | - | Upgrade |
Impairment of Goodwill | - | - | -3.91 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 5.21 | Upgrade |
Pretax Income | -99.73 | -35.02 | -31.53 | -41.63 | -84.55 | -67.18 | Upgrade |
Income Tax Expense | 0.15 | 0.11 | 0.01 | 0.03 | -0.2 | -2.79 | Upgrade |
Earnings From Continuing Operations | -99.88 | -35.13 | -31.54 | -41.66 | -84.35 | -64.38 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | -0.03 | 0.88 | Upgrade |
Net Income | -99.88 | -35.13 | -31.54 | -41.66 | -84.38 | -63.5 | Upgrade |
Preferred Dividends & Other Adjustments | -0.18 | - | - | - | - | - | Upgrade |
Net Income to Common | -99.7 | -35.13 | -31.54 | -41.66 | -84.38 | -63.5 | Upgrade |
Shares Outstanding (Basic) | 11 | 4 | 0 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 11 | 7 | 0 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | 450.90% | 2599.19% | 608.45% | 8.32% | 41.86% | 28.52% | Upgrade |
EPS (Basic) | -8.74 | -7.94 | -113.58 | -1062.65 | -2331.41 | -2489.12 | Upgrade |
EPS (Diluted) | -8.74 | -20.91 | -113.58 | -1062.65 | -2331.41 | -2489.12 | Upgrade |
Free Cash Flow | -52.26 | -49.06 | -30.84 | -26.85 | -71.01 | -40.6 | Upgrade |
Free Cash Flow Per Share | -4.58 | -6.54 | -111.04 | -684.81 | -1961.95 | -1591.55 | Upgrade |
Gross Margin | - | - | - | -43.98% | - | -276.70% | Upgrade |
Operating Margin | -34632.29% | -9267.80% | -1218.50% | -165.86% | -1521.56% | -705.99% | Upgrade |
Profit Margin | -51927.60% | -7965.76% | -1639.50% | -230.78% | -1563.10% | -947.90% | Upgrade |
Free Cash Flow Margin | -27216.67% | -11123.81% | -1602.81% | -148.72% | -1315.39% | -606.09% | Upgrade |
EBITDA | -66.1 | -40.7 | -23.29 | -29.77 | -80.48 | -45.45 | Upgrade |
EBITDA Margin | - | - | - | -164.94% | - | - | Upgrade |
D&A For EBITDA | 0.4 | 0.17 | 0.16 | 0.17 | 1.66 | 1.84 | Upgrade |
EBIT | -66.49 | -40.87 | -23.44 | -29.94 | -82.13 | -47.29 | Upgrade |
EBIT Margin | - | - | - | -165.86% | - | - | Upgrade |
Revenue as Reported | 0.19 | 0.44 | 1.92 | 18.05 | 5.4 | 6.7 | Upgrade |
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.